ICMJE DISCLOSURE FORM

Date: June, 9th, 2022 Your Name: Carlo Aleci

Manuscript Title: Psychophysics in the ophthalmological practice. I. Visual Acuity

Manuscript number (if known): AES 22-25

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone	
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity(if not indicated in item #1 above).	XNone	
3	Royalties or licenses	None related to the content of this manuscript	Eyenext s.r.l.;Royalties due for the TETRA Analyzer, a device developed to assess visuoperceptual alterations in dyslexic children. Notrelated to the content of this manuscript . Royalties due for my books: -Dislessia Evolutiva: L'approccio Visivo, LaFeltrinelli, Milano, 2014.

			-Interpretare il Tetra, LaFeltrinelli, Milano, 2015Measuring the Soul: Psychophysics for non-Psychophysicists. EDP Science publisher, Les Ulis, France, 2021. Italian edition: Misurare l'Anima. Introduzione alla Psicofisica per non Psicofisici, LaFeltrinelli, Milano, 2014, 2° edizione: 2016Manuale di Oculistica-per le scuole elementary, Lampi laFeltrinelli, Milano, 2022. Notrelated to the content of this manuscript.
4	Consulting fees	none	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None related to the content of this manuscript	Esavision Technology: Paid lessons on dyslexia and perception. Notrelated to the content of this manuscript
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	No patent planned, issued or pending for the TETRA Analyzer and for the oktotype . "Oktotype" is just the name of a prototype and as such not commercially available. The suffix TM has been removed as it was wrongly added to make clear the term "oktotype" did not refer to a scientific procedure but to a specific instrument.
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	

	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please summarize the above conflict of interest in the following box:

The author Carlo Aleci reports in the past 36 months royalties paid for the development of the Tetra Analyzer, royalties due for 4 books and paid lectures on dyslexia and perception, none of them related to the content of the current manuscript. He certifies that the prototype "oktotype", cited at the end of the manuscript, is not a trademark and that is not commercially available. He declares no patents planned, issued or pending for the TETRA and for the oktotype.

Therefore, the author Carlo Aleci declares no relationships/activities/interests related to the content of the manuscript.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: <u>June 9th, 2022</u>

Your Name: Claudio Rosa

Manuscript Title: Psychophysics in the ophthalmological practice. I. Visual Acuity

Manuscript number (if known): AES-22-25

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			p
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		
	No time innit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity(if not indicated in		
	item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

_	Daymant and a	V N	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

Please summarize the above conflict of interest in the following box:

The author Claudio Rosa declares no relationships/activities/interests related to the content of the manuscript.

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.